Drug transport and metabolism of novel anticancer drugs

Bibliography

• HJoyce, AMcCann, MClynes, et al. Influence of multi-drug resistance and drug transport proteins on chemotherapy drug metabolism. Expert Opin Drug Metab Toxicol 2015;11(5):795–809
   PubMed Web of Science ®Google Scholar
• DFabbro, SWCowan-Jacob, HMoebitz. 10 things you should know about protein kinases. IUPHAR Review 14. Br J Pharmacol 2015. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• GJPeters, SPAckland. New antimetabolites in preclinical and clinical development. Expert Opin Invest Drugs 1996;5:637–79
   Google Scholar
• VTDeVitaJr, EChu. A history of cancer chemotherapy. Cancer Res 2008;68(21):8643–53
   PubMed Web of Science ®Google Scholar
• MGRots, RPieters, GJKaspers, et al. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Brit J Haematol 2000;110:791–800
   PubMed Web of Science ®Google Scholar
• JCiccolini, RFanciullino, CSerdjebi, et al. Pharmacogenetics and breast cancer management: current status and perspectives. Expert Opin Drug Metab Toxicol 2015;11(5):719–29
   PubMed Web of Science ®Google Scholar
• SGChaney, SLCampbell, EBassett, et al. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005;53(1):3–11
   PubMed Web of Science ®Google Scholar
• FBroekman, EGiovannetti, GJPeters. Tyrosine kinase inhibitors: multitargeted or single-targeted? World J Clin Oncol 2011;2:80–93
   PubMedGoogle Scholar
• MJMauro, BJDruker. STI571: targeting BCR-ABL as therapy for CML. Oncologist 2001;6(3):233–8
   PubMed Web of Science ®Google Scholar
• KEechoute, ASparreboom, HBurger, et al. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 2011;17(3):406–15
   PubMed Web of Science ®Google Scholar
• GHamilton, BRath, OBurghuber. Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol 2015;11(5):835–42
   PubMed Web of Science ®Google Scholar
• EGuttman-Yassky, AMita, MDe Jonge, et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010;46(11):2010–19
   PubMed Web of Science ®Google Scholar
• PBoudou-Rouquette, OHuillard, JArrondeau, et al. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: Consequences for the clinical management of sorafenib and regorafenib. Expert Opin Drug Metab Toxicol 2015;11(5):785–94
   PubMed Web of Science ®Google Scholar
• JChen, DLiu, XZheng, et al. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug–drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling. Expert Opin Drug Metab Toxicol 2015. [ Epub ahead of print]
   Web of Science ®Google Scholar
• HPopilsky, DStepensky, et al. Mathematical modeling analysis of intratumoral disposition of anticancer agents and drug delivery system. Expert Opin Drug Metab Toxicol 2015;11(5):767–84
   PubMed Web of Science ®Google Scholar
• CGDa Silva, RJHoneywell, HDekker, et al. Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters. Expert Opin Drug Metab Toxicol 2015;11(5):703–17
   PubMed Web of Science ®Google Scholar
• KGGotink, HJBroxterman, MLabots, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 2011;17:7337–46
   PubMed Web of Science ®Google Scholar
• CSerdjebi, GMilano, JCiccolini. Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. Expert Opin Drug Metab Toxicol 2014;11(5):665–72
   PubMed Web of Science ®Google Scholar
• SMatsusaka, HJLenz. Pharmacogenomics of fluorouracil-based chemotherapy toxicity. Expert Opin Drug Metab Toxicol 2015;11(5):811–21
   PubMed Web of Science ®Google Scholar
• AWojtuszkiewicz, YGAssaraf, MJMaas, et al. Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug. resistance. Expert Opin Drug Metab Toxicol 2014;11(5):673–89
   PubMed Web of Science ®Google Scholar
• MJoerger. Metabolism of the taxanes including nab-paclitaxel. Expert Opin Drug Metab Toxicol 2014;11(5):691–702
   PubMed Web of Science ®Google Scholar
• JRobert, VLe Morvan, EGiovannetti, et al. On the use of pharmacogenetics in cancer treatment and clinical trials. Eur J Cancer 2014;50:2532–43
   PubMed Web of Science ®Google Scholar
• MHamilton, JLWolf, JRusk, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12(7 Pt 1):2166–71
   PubMed Web of Science ®Google Scholar
• MO’Malley, ANKing, MConte, et al. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy. for lung cancer. J Thorac Oncol 2014;9(7):917–26
   PubMed Web of Science ®Google Scholar